Resistant hypertension responding to change from furosemide to thiazide: understanding calcium channel blocker-related edema.
Kaiser Permanente, Anaheim, CA, USA. joel.handler@kp.org
Joel
J
Handler
D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use; D000368:Aged; D001794:Blood Pressure / Q000502:physiology; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004487:Edema / Q000139:chemically induced* / Q000503:physiopathology; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D058671:Adrenergic beta-1 Receptor Antagonists; D002121:Calcium Channel Blockers; D049993:Sodium Chloride Symporter Inhibitors; D005665:Furosemide; D008790:Metoprolol; D019808:Losartan